Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04148742
Recruitment Status : Suspended (Clinical development strategy adjustment, non-safety reason)
First Posted : November 1, 2019
Last Update Posted : June 11, 2021
Information provided by (Responsible Party):
Dizal Pharmaceuticals

No Study Results Posted on for this Study
Recruitment Status : Suspended
Estimated Primary Completion Date : July 2023
Estimated Study Completion Date : July 2023